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We developed a vaccine construct in which a BVP22 domain and an invariant-chain major histocompatibility
complex class II-targeting motif capable of enhancing dendritic cell antigen uptake and presentation were
fused to a sequence encoding a B- and T-cell antigen from the Anaplasma marginale major surface protein 1a
and tested whether this construct would prime and expand immune responses in outbred calves. A single
inoculation with this construct effectively primed the immune responses, as demonstrated by a significant
enhancement of CD4 T-cell proliferation compared to that in calves identically inoculated but inoculated with
a DNA construct lacking the targeting domains and compared to that in calves inoculated with an empty vector.
These proliferative responses were mirrored by priming and expansion of gamma interferon-positive CD4 T
cells and immunoglobulin G responses against the linked B-cell epitope. Priming by the single immunization
induced memory that underwent rapid recall following reexposure to the antigen. These results demonstrate
that DNA vaccines targeting key intercellular and intracellular events significantly enhance priming and
expansion and support the feasibility of single-dose DNA immunization in outbred populations.
The ability to prime and expand immune responses with a
single immunogen is critically important for humans, for whom
vaccine coverage inversely correlates with the number of
booster immunizations required, and for livestock, for which
economic considerations drive vaccine delivery. Nucleic acid-
based vaccination is a contemporary strategy for single-dose
priming and expansion of antigen-specific B- and T-lympho-
cyte responses against infectious organisms in animals and
humans (12, 28). Host cell transfection by a DNA vaccine
construct allows prolonged intracellular antigen expression,
mimicking the effect of a live vaccine (10, 35). The expressed
antigen can be processed and presented by the transfected cells
or released through secretion or lysis. The released antigen is
available for B-cell receptor recognition and follicular den-
dritic cell (DC) entrapment, or it is taken up by other profes-
sional antigen-presenting cells (APCs), which present epitopes
from the antigen to T lymphocytes in the context of major
histocompatibility complex (MHC) and costimulatory mole-
cules (5, 18, 31). The immunogenicity of DNA vaccines and the
ability of modified vectors to enhance immunity have been
clearly demonstrated in mice, but translating the results from
mouse models to the outbred species that represent the actual
populations to be protected by vaccination has proven to be a
challenging barrier to the deployment of DNA vaccines (13,
33). Results from trials with outbred species, including hu-
mans, have shown that DNA vaccines induce suboptimal and
inconsistent immune responses, even after multiple immuniza-
tions with high vaccine doses (3, 4, 9, 33, 34). While alternative
approaches, such as priming with a DNA vaccine and boosting
with either a protein immunogen or a viral construct, have
been shown to effectively expand the immune response, these
approaches negate a compelling rationale for nucleic acid vac-
cines: priming and expansion with a single immunization.
DCs are the key APCs required for priming of an immune
response following DNA vaccination; however, they constitute
1% of the nucleated cells in any tissue, and only about 0.4% of
DCs are normally transfected following DNA vaccination (8, 26).
Somatic cells, which are poor APCs incapable of initiating pri-
mary immune responses, are the main transfectants following
DNA vaccination (1, 14, 29). However, the DNA-encoded anti-
gen is poorly expressed and released from the transfected somatic
cells for uptake by DCs (5, 11). Consequently, a strategy that
facilitates efficient intercellular trafficking of a DNA-encoded an-
tigen at a DC-enriched immunization site (24) is predicted to
significantly increase the number of DCs acquiring and processing
the antigen for presentation to T lymphocytes. We focused on
testing of an improved DNA vaccination strategy directed at
priming and expanding B- and T-lymphocyte responses in out-
bred species following immunization with a single dose. Specifi-
cally, we developed a strategy to promote intercellular trafficking
and intracellular targeting of a defined MHC-restricted DNA-
encoded T-cell epitope and a linked B-cell epitope at a DC-
enriched intradermal immunization site and tested this strategy
using calves as the model population for outbred animals. The
goal of this study was to test whether immunization with a single
dose of a DNA vaccine capable of intercellular trafficking and
targeting of the intracellular MHC class II pathway effectively
primes and expands antigen-specific CD4 T cells in an outbred
animal species.
* Corresponding author. Present address: Veterinary Pathobiology,
Texas A&M University, College Station, TX 77843. Phone: (979) 845-
4615. Fax: (979) 862-2344. E-mail: wmwangi@cvm.tamu.edu.
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MATERIALS AND METHODS
Plasmid construction and purification. The generation of DNA constructs
expressing bovine FLT3L and granulocyte-macrophage colony-stimulating factor
(GM-CSF) as molecular adjuvants in the VR-1055 eukaryotic expression vector
(Vical, San Diego, CA) has been described previously (24); these constructs are
designated FLT3L and GM-CSF, respectively, in this study. Five vaccine con-
structs were used in the present study. BVP22 was generated by linking in-frame
the sequences encoding the bovine VP22 intercellular trafficking domain, the
Anaplasma marginale major surface protein 1a (MSP1a) DRB3*1101-restricted
F2-5 epitope (GGVSYNDGNASAARSVLETLAGHVDALGIS), a defined
MSP1a B-cell epitope (QASTSS), and FLAG tag (DYKDDDDK) (Fig. 1A)
(23). BVP22R is identical to BVP22, except that the bvp22 sequence is in the
reverse orientation and is thus nonfunctional but retains the open reading frame
(Fig. 1B) (23). The sequence encoding the adaptor protein 2 (AP-2) binding
endosome/lysosome-targeting motif (MEDQRDLISNHEQLPMLGQRPGAQE
SKCSR) from the bovine invariant chain (25), designated IC, was added in-frame
at the 5 end of BVP22 by overlap extension PCR (22) with the following
primers: ICBVP22 Fwd 1 (5-ATAGATATCATGGAAGACCAGCGTGACCT
CATCTCCAACCATG AGCAGCTG-3), ICBVP22 Fwd 2 (5-ATCTCCAAC
CATGAGCAGCTGCCCATGCTGGGCCAGCGCCCCGGAGCCCAGGA
GAGCAAG-3), ICBVP22 Fwd 3 (5-CCCGGAGCCCAGGAGAGCAAGTG
CAGTCGTATGGCCCGGTTCCACAGGCCC-3), and FLAG Rev (5-ATAA
GATCTTACTTATCGTCATCGTCCTTGTAGTC-3). The ICBVP22 Fwd 1
primer introduced an EcoRV restriction site (in boldface) at the 5 end, whereas
the FLAG Rev primer introduced a BglII restriction site (in italics) at the 3 end.
The EcoRV-BglII fragment was ligated into an EcoRV-BamHI-digested VR-
1055 vector to generate a construct designated IC.BVP22 (Fig. 1C). The se-
quence encoding the lysosome-targeting motif (RKRSHAGYQTI) from the
cytoplasmic domain of bovine lysosomal-associated membrane protein 1
(LAMP-1) (17), designated GpIIa, was added in-frame at the 3 end of the
BVP22F2-5FLAG chimeric gene by using the BVP22 forward primer (5-ATA
GATATCATGGCCC GGTTCCACAGGCCC-3) and the FLAG GpIIa reverse
primer (5-ATAAGATCTTAGATGGTCTGGTAGCCGGCGTGGCTCCTCT
TCCGCTTATCGTCATCGTCCTTGTAGTC-3). The forward primer intro-
duced an EcoRV restriction site (in boldface) at the 5 end, and the reverse primer
introduced a BglII restriction site (in italics) at the 3 end. The EcoRV-BglII frag-
ment was ligated into EcoRV-BamHI-digested VR-1055 to generate a construct
designated BVP22.GpIIa (Fig. 1D). To test whether a combination of the IC and
GpIIa motifs would have a synergistic effect on endosome-lysosome antigen target-
ing, the sequence encoding the GpIIa motif was added in-frame at the 3 end of
IC.BVP22 to generate a construct designated IC.BVP22.GpIIa (Fig. 1E).
To generate a recombinant protein for enzyme-linked immunosorbent assay
(ELISA) measurement of antibody and for testing of recall responses, the human
CD5 secretory signal sequence was linked in-frame to the sequence encoding the
chimera, described above, containing the F2-5 epitope, the MSP1a B-cell
epitope, and the FLAG tag epitope (DYKDDDDK) by overlap extension PCR.
The resultant chimeric gene was subcloned into VR-1055 as an EcoRV-BamHI
fragment to generate a construct designated MSP1aBT. The constructs described
above and the unmodified VR-1055 vector were amplified in Escherichia coli
DH5 cells (Invitrogen, Carlsbad, CA), and large-scale plasmid DNA was puri-
fied with Endo-Free Plasmid Gigaprep kits (QIAGEN, Valencia, CA). The DNA
was ethanol precipitated and resuspended in clinical-grade normal saline (Ab-
bott Laboratories, North Chicago, IL). The endotoxin content in the plasmid
DNA preparations was measured with a Limulus amebocyte assay kit (BioWhit-
taker, Walkersville, MD) and was 5 endotoxin units/mg in all samples.
Protein expression and intercellular spreading. The expression and in vivo
adjuvant activities of the FLT3L and GM-CSF constructs have been reported
previously (24). Protein expression by the BVP22, BVP22R, IC.BVP22,
BVP22.GpIIa, and IC.BVP22.GpIIa constructs was confirmed by immunocyto-
metric analysis of transfected human embryonic kidney (HEK) 293-F cells (In-
vitrogen), as described previously (23). Briefly, 293-F cell monolayers at 60%
confluence were transfected with 0.2 g of the DNA constructs by using Lipo-
fectamine 2000 (Invitrogen). The 293-F cells transfected with the BVP22 con-
struct served as a positive control, whereas the VR-1055 empty vector served as
a negative control (23). The transfected cells were incubated with a 1/1,000
dilution of a mouse anti-FLAG M2–alkaline phosphatase conjugate (Sigma, St.
Louis, MO) in blocking buffer (1 phosphate-buffered saline [PBS] with 5%
fetal bovine serum). Duplicate transfected monolayers were reacted with an
isotype control monoclonal antibody (MAb), and following washes in blocking
buffer, the monolayers were incubated with a 1/1,000 dilution of alkaline phos-
phatase-conjugated goat anti-mouse MAb (Jackson ImmunoResearch Labora-
tories, West Grove, PA) in blocking buffer. Following washes in blocking buffer,
the alkaline phosphatase activity was detected by using the Fast Red TR–Naph-
thol AS-MX substrate (Sigma). Stained cells were visualized and photographed
with an inverted phase-contrast microscope (model CK-2; Olympus Optical,
Tokyo, Japan). Recombinant MSP1aBT was expressed as a FLAG-tagged pro-
tein in 293 Free-Style cells (Invitrogen) and was affinity purified with anti-FLAG
M2 agarose beads (Sigma).
BVP22-directed intercellular spreading was evaluated in 293-F cells trans-
fected with 0.05 g DNA, followed by immunocytometric analysis with the
mouse anti-FLAG M2–alkaline phosphatase conjugate (Sigma); and spreading
was quantified by flow cytometry with a mouse anti-FLAG M2–fluorescein iso-
thiocyanate conjugate (Sigma) following intracellular staining of cells transfected
with 0.2 g DNA, as described previously (23).
Effect of endosome/lysosome-targeting motifs on antigen presentation. The
influence of the endosome/lysosome-targeting IC and GpIIa motifs on MHC
class II epitope presentation by DCs following BVP22-directed intercellular
trafficking was evaluated by proliferation assays with monocyte-derived DCs and
F2-5-specific CD4 T cells, as described previously (23). Briefly, 293-F cells were
transfected with 0.2 g of BVP22, BVP22R, IC.BVP22, BVP22.GpIIa, or
IC.BVP22.GpIIa DNA. The VR-1055 vector served as a negative control (23).
One day posttransfection, the HEK 293-F cell transfectants were harvested,
FIG. 1. DNA vaccine constructs. Eukaryotic expression constructs were generated in the VR-1055 vector, which contains the cytomegalovirus
promoter (CMVP). (A) BVP22 encodes the bovine VP22 intercellular spreading domain linked in-frame to the A. marginale MSP1a DRB3*1101-
restricted F2-5 epitope and the defined MSP1a B-cell epitope (23); (B) BVP22R is identical to BVP22, except that the bvp22 sequence is in the
reverse orientation and is nonfunctional; (C) IC.BVP22 encodes the bovine invariant-chain endosome/lysosome targeting motif, the IC motif, at
the 5 end of BVP22; (D) BVP22.GpIIa encodes the LAMP-1 lysosome-targeting motif, the GpIIa motif, at the 3 end of BVP22;
(E) IC.BVP22.GpIIa contains the IC motif at the 5 end and the GpIIa motif at the 3 of BVP22. A FLAG tag was added to each construct for
analysis of protein expression by immunocytochemistry and intercellular spreading.
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washed with PBS, and then mixed at a ratio of 3:1 with monocyte-derived DCs
at the fifth day of differentiation. The cell mixture was plated on poly-D-lysine
(Sigma-Aldrich)-coated 100-mm petri dishes and left overnight to establish a
mixed cell monolayer with maximum cell-to-cell contact (23). The DCs were
labeled with mouse anti-bovine DEC-205 MAb CC98 (15), followed by positive
selection with goat anti-mouse immunoglobulin G (IgG) microbeads (Miltenyi
Biotec, Auburn, CA). The purities and the phenotypes of the isolated DCs were
confirmed by flow cytometry, as described previously (23). Irradiated (3,000-rad)
DCs (2.5  103, 5  103, or 104 cells per well) were cultured in triplicate wells
with 2  104 MSP1a F2-5 epitope-specific short-term CD4 T cells generated
from MSP1-immunized calf 87 (7). The cells were radiolabeled for the last 18 h
of culture with 0.25 Ci [3H]thymidine, harvested with an automated cell har-
vester (Tomtec, Orange, CT), and counted with a liquid scintillation counter.
The results are presented as the mean counts per minute (1 standard deviation
[SD]) of [3H]thymidine incorporation. The significance of the differences in
proliferation of the F2-5-specific CD4 T cells among the DC treatments was
determined by analysis of variance (ANOVA), followed by Bonferroni’s multi-
ple-comparison test, and a P value of 0.05 was considered significant.
Immunization of calves. Typing for bovine MHC class I and class II (DRB3)
was done by microarray hybridization, as described previously (27), and 14
DRB3*1101-positive male Holstein calves (age, 6 months) seronegative for A.
marginale were selected for use in this study. Peripheral blood mononuclear cells
(PBMCs) from these calves were tested in a proliferation assay with A. marginale
antigens and were found to be nonresponsive. The calves were allocated to three
groups, and all were inoculated intradermally with a mixture of 2 mg of DNA
encoding the molecular adjuvants bovine FLT3L and GM-CSF to recruit DCs to
the intradermal immunization site (24) (Table 1). Three days later, group 1
calves (n 	 5) were inoculated with 3 mg of the IC.BVP22 construct at the same
intradermal site where the cytokine constructs were injected. Group 2 calves
(n 	 5) were similarly inoculated but were inoculated with the BVP22R con-
struct, in which the bvp22 sequence is present but in the reverse orientation and
is thus nonfunctional (23). The control calves, which were in group 3 (n 	 4),
were inoculated with the VR-1055 empty vector. To test whether the primed
immune responses could undergo rapid recall upon antigen reexposure, the
calves were inoculated with 20 g of the recombinant MSP1aBT protein emul-
sified in alum (Pierce, Rockford, IL) on day 105 postimmunization, and the recall
responses were evaluated within 96 h.
Detection of F2-5-specific lymphocytes by ELISPOT assay. To detect F2-5-
specific T lymphocytes, gamma interferon (IFN-
)-positive (IFN-
) T cells in
CD8 
 PBMCs were quantified by an enzyme-linked immunospot (ELIS-
POT) assay 11 days postvaccination and weekly thereafter. Depletion of CD8
and 
 T lymphocytes was done by incubating PBMCs with CD8-specific MAb
7C2B and 
 T-cell receptor-specific MAb GB21A (Monoclonal Antibody Cen-
ter, Washington State University), followed by immunomagnetic separation with
goat anti-mouse IgG micro beads (Miltenyi Biotec). The efficiency of depletion
was confirmed by flow cytometry with the CD8- and 
-specific MAbs. Whole
PBMCs were used for all assays after day 46 postimmunization, as direct com-
parison of PBMCs and CD4 T cells isolated from PBMCs revealed no differ-
ences. Bovine IFN-
-specific ELISPOT assays were conducted in triplicate wells
of MultiScreen-HA plates (Millipore), as described previously (36). Briefly,
0.5  106 CD8 
 PBMCs or PBMCs were added in 100-l volumes contain-
ing complete RPMI 1640 medium with 10 g/ml F2-5 peptide or a negative
control peptide, MSP2-P1 (6). The positive control was medium containing 10
g/ml concanavalin A, whereas medium alone served as a negative control. After
incubation for 36 h at 37°C, the plates were washed, developed, and dried
overnight. The spots were quantified with an ELISPOT reader (Cell Technology)
and AID 2.9 software (AutoImmun Diagnostika). For each sample, the mean
number of spots in the negative control wells was subtracted from the mean
number of spots in the test wells to determine the mean number of F2-5-specific
IFN-
-secreting T lymphocytes or spot-forming cells. The results are presented
as the mean number of spot-forming cells per 106 CD8 
 PBMCs or PBMCs.
The significance of the differences in F2-5-specific IFN-
 T-cell responses
among the groups was analyzed by ANOVA, followed by Bonferroni’s multiple-
comparison test, and a P value of 0.05 was considered significant.
Proliferation assays. Proliferation assays were conducted essentially as de-
scribed previously (6). Briefly, CD8 
 PBMCs or PBMCs (2 105 cells) were
cultured in triplicate wells of round-bottom 96-well plates (Costar) for 3 days in
a total volume of 100 l of complete medium containing 10 g/ml F2-5 peptide
or the negative control peptide, MSP2-P1(6). The positive control was medium
containing 2.5 g/ml concanavalin A, whereas medium alone served as a negative
control. Cells were radiolabeled, harvested, and counted as described above. The
results are presented as the mean counts per minute (1 SD) of [3H]thymidine
incorporation. The significance of the differences in proliferation among groups
was determined by ANOVA, followed by Bonferroni’s multiple-comparison test,
and a P value of 0.05 was considered significant.
MSP1aBT-specific IgG titers. ELISA was used to determine the MSP1aBT-
specific IgG titers, as described previously (36). Briefly, ELISA microplates were
coated with 100 l of 50 ng/ml affinity-purified rMSP1aBT in coating buffer (0.05
M Na2CO3, pH 9.6) overnight at 4°C, washed, and then blocked with 5% milk in
PBS with 0.1% Tween 20. The serum was diluted (1:100 to 1:100,000) in blocking
buffer, and 100 l/well was added to duplicate wells. Following the washes, 100
l/well of 1:500 recombinant protein G-horseradish peroxidase (Invitrogen) was
added, and the plates were incubated for 1 h at room temperature. After the
plates were washed, 100 l/well tetramethylbenzidine substrate (Invitrogen)
were added to the plates, the plates were incubated for 1 h, and 100 l/well STOP
buffer (1 N hydrochloric acid) was added. The optical density at 450 nm was
determined with a Titertek Multiscan MCC/340 microplate reader (MTX Lab
Systems). The significance of the difference in MSP1aBT-specific IgG titers
among the groups was determined by ANOVA, followed by Bonferroni’s mul-
tiple-comparison test, and a P value of 0.05 was considered significant.
RESULTS
Invariant chain AP-2 binding motif enhances DC epitope
presentation. The BVP22 chimeric construct (Fig. 1A) (23)
was modified by adding the sequence encoding the bovine
invariant-chain endosome/lysosome-targeting (IC) motif (25)
at the 5 end or the sequence encoding the lysosome-targeting
motif (17) from bovine LAMP-1 (GpIIa) at the 3 end to
generate chimeric constructs designated IC.BVP22 (Fig. 1C)
and BVP22.GpIIa (Fig. 1D), respectively. In addition, a single
construct with both the IC and the GpIIa motifs, designated
IC.BVP22.GpIIa (Fig. 1E), was developed and tested to de-
termine if there was an additive or synergistic effect from use
of the combination of the two targeting motifs. Each construct
expressed protein at equivalent levels; and each construct with
the BVP22 in the correct orientation similarly directed inter-
cellular trafficking at equivalent levels, as confirmed by immu-
nocytometric analysis (Fig. 2) and flow cytometric analysis
(data not shown) of transfected 293-F cells (23). The BVP22R
TABLE 1. Immunization protocola
Group no. Calf no. DRB3 alleleb DNA vaccinec
1 3892 1101/1201 IC.BVP22
3937 1001/1101 IC.BVP22
3943 1501/1101 IC.BVP22
3945 0101/1101 IC.BVP22
3959 1001/1101 IC.BVP22
2 3939 1101/1201 BVP22R
3982 1001/1101 BVP22R
3985 1501/1101 BVP22R
3992 0101/1101 BVP22R
4000 1001/1101 BVP22R
3 3960 1101/1201 VR-1055
3962 1101/0201 VR-1055
3989 1101/1501 VR-1055
3991 1401/1101 VR-1055
a Calves were inoculated intradermally with the DNA molecular adjuvant
constructs encoding FLT3L and GM-CSF at 2 mg each (24). The calves were
then reexposed to antigen by inoculation of recombinant MSP1aBT protein at 20
g, and recall responses were evaluated within 96 h.
b MHC class II DRB3 alleles were defined by microarray analysis of exon
2 (27).
c Calves were inoculated with the DNA construct encoding the antigen or the
VR-1055 vector alone (each at 3 mg) at the same site where the cytokine
constructs were injected.
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construct (Fig. 1B) served as a negative control for intercellu-
lar spreading (23). The effect of the targeting motifs on antigen
presentation was determined by proliferation assays with F2-
5-specific CD4 T cells and graded numbers of DCs positively
selected from overnight monolayer cocultures of nontrans-
fected DCs and 293-F cells transfected with each construct.
The addition of the IC motif at the N terminus of the BVP22/
antigen chimera directed significantly greater DC presentation
of F2-5 to CD4 T cells compared to that achieved with all
other constructs (Fig. 3), including those with the GpIIa-tar-
geting motif at the C terminus or the combination of the
N-terminal IC motif and the C-terminal GpIIa motif. The
impact of the IC motif on DC F2-5 presentation to CD4 T
cells (P  0.001) was most evident with lower numbers of DCs
(Fig. 3).
A single immunization primes CD4 T-cell and B-cell re-
sponses. On the basis of the ability of the IC.BVP22 construct
to enhance presentation of the antigen to T cells in vitro, this
construct was used to immunize calves and to test its ability to
prime cells following a single immunization. Priming of F2-5-
specific T cells was tested by an IFN-
-specific ELISPOT assay
and T-cell proliferation. B-cell priming was evaluated by mea-
suring the titers of antibody to the linked B-cell epitope (2).
Inoculation of calves with a single dose of the IC.BVP22 con-
struct (Fig. 1C) at a DC-enriched intradermal site effectively
primed F2-5-specific CD4 T-cell responses (Fig. 4A). All five
IC.BVP22-immunized calves had significant (P  0.05) in-
creases in the number of IFN-
-secreting CD4 T cells within
11 days following a single DNA inoculation compared both to
their preimmunization numbers and to the numbers in the five
calves immunized on an identical schedule with the VR-1055
vector (Fig. 4A). This priming was also evident when the level
of proliferation of CD4 T cells (Fig. 4B) and the IgG titer
against the linked B-cell epitope (Fig. 4C) were compared to
their preimmunization levels and titers and to those of the
control calves inoculated with the VR-1055 vector. Compared
to the results of immunization with the control BVP22R
construct lacking the functional BVP22 trafficking domain
(the bvp22-coding sequence is in the reverse orientation)
and the IC-targeting motif (Fig. 1B), a single immunization
with the IC.BVP22 construct induced significantly greater
mean numbers of IFN-
 CD4 T cells (P  0.05; Fig. 4A),
higher mean levels of proliferation of CD4 T cells (P 0.001;
Fig. 4B), and higher IgG titers (P  0.01; Fig. 4C).
Maintenance and expansion of IC.BVP22-primed re-
sponses. The kinetics of the F2-5-specific IFN-
 CD4 T-cell
precursor frequency postimmunization were evaluated weekly
for 3 months by an IFN-
-specific ELISPOT assay, whereas
T-cell proliferation was evaluated by determination of the level
of [3H]thymidine incorporation and IgG titers by ELISA. The
F2-5-specific IFN-
 CD4 T-cell responses primed by the
single-dose IC.BVP22 DNA vaccine immunization continued
to increase and remained significantly greater (P  0.001)
throughout the postpriming period compared to those in calves
identically inoculated but inoculated with the DNA construct
lacking the targeting domains or to those in calves inoculated
with the VR-1055 vector (Fig. 5A). The proliferation of F2-5-
specific CD4 T cells diminished slightly over time but re-
mained significantly greater (P  0.001) in the postimmuniza-
tion period compared to the proliferation of CD4 T cells for
control vaccinees inoculated with the construct lacking the
targeting domains or for calves inoculated with the VR-1055
vector (Fig. 5B). Consistent with the CD4 T-cell responses in
the IC.BVP22 vaccinees, the IgG titer against the linked B-cell
epitope increased and remained significantly greater (P 
0.001) than that for the controls (Fig. 5C). Most importantly,
there was a significant expansion of F2-5 specific IFN-

FIG. 2. In vitro protein expression following transfection with the vaccine constructs. Monolayers of HEK 293-F cell transfectants were
evaluated for protein expression by in situ immunocytochemistry with a mouse anti-FLAG–alkaline phosphatase conjugate. (A) Cells transfected
with the VR-1055 vector; (B) cells transfected with the IC.BVP22 construct; (C) cells transfected with the BVP22.GpIIa construct; (D) cells
transfected with the IC.BVP22.GpIIa construct. Protein expression by the BVP22 and the BVP22R constructs has been reported previously (23).
FIG. 3. Invariant chain AP-2 binding motif enhances DC epitope
presentation. The effects of the endosome/lysosome-targeting IC and
GpIIa motifs on epitope presentation to F2-5-specific CD4 T cells
were tested by proliferation assays with irradiated DCs positively se-
lected from overnight monolayer cocultures of nontransfected DCs
and transfected 293-F cells. Proliferation of the F2-5-specific CD4 T
cells is presented as the mean counts per minute (1 SD) of [3H]thy-
midine incorporation. The significance of the differences in prolifera-
tion was determined by ANOVA, followed by Bonferroni’s multiple-
comparison test, and a P value of 0.05 was considered significant.
The mean response to IC.BVP22 was significantly different from that
for all other groups when a DC/T-cell ratio of 1:2 (, P  0.05), 1:4
(†, P  0.01), or 1:8 (‡, P  0.001) was used in the proliferation assay.
The symbols represent BVP22 (), BVP22R (x), IC.BVP22 (),
BVP22.GpIIa (F), IC.BVP22.GpIIa (Œ), and the VR-1055 vector (E).
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CD4 T-cell and IgG responses by the IC.BVP22 vaccinee
(calf 3937) that initially had the lowest responses 11 days
postimmunization (Fig. 5A,C).
IC.BVP22 primed B- and T-cell responses undergo rapid
recall. To determine the magnitude of the memory responses
induced by the single immunization with the DNA vaccine, the
vaccinees were inoculated with recombinant MSP1aBT protein
on day 95 postimmunization, and the recall responses were
evaluated within 96 h. The IC.BVP22-primed T-cell and B-cell
responses underwent rapid recall, with increases in the number
of F2-5 specific IFN-
 CD4 T cells (Fig. 6A), the level of
F2-5-specific T-cell proliferation (Fig. 6B), and the titer of
antibody to the linked B-cell epitope (Fig. 6C) compared to the
levels and titers prior to reexposure in the same animals (Fig.
5A to C). There were no increases in F2-5-specific IFN-

CD4 T cells, T-cell proliferation, or antibody titers in the
calves initially inoculated with the VR-1055 vector and then
given MSP1aBT protein (Fig. 5A to C), clearly demonstrating
that these were indeed recall responses rather than de novo
induction. The recall responses for the IC.BVP22-primed
calves were most dramatic for F2-5-specific T-cell proliferation
(20-fold increase), with more modest increases in both the
mean antibody titer (fivefold) and the mean number of F2-5-
specific IFN-
 CD4 T cells (two- to threefold). In contrast,
there was no to a minimal recall response in the calves initially
immunized with the BVP22R DNA construct lacking the func-
tional targeting domains (Fig. 5A to C), demonstrating that the
differences in the recall responses were attributable to the
effect of the targeting and trafficking domains on the initial
priming.
DISCUSSION
Incorporation of the invariant-chain endosome/lysosome-
targeting (IC) motif to the N terminus of BVP22 significantly
improved DC presentation of a CD4 T-cell epitope to cog-
nate T cells. This finding is consistent with those from earlier
studies, in which the IC endosome/lysosome-sorting motif di-
rected endogenously synthesized proteins to efficiently enter
the MHC class II presentation pathway (30), and demonstrates
that it similarly targets antigens encoded by DNA vaccines.
The impact of the IC motif on DC F2-5 presentation to CD4
T cells was most evident with lower numbers of DCs, and this
is most representative of the in vivo situation, in which DCs
constitute 1% of nucleated cells in any tissue (8, 26). Com-
pared to the effects of BVP22 alone and to BVP22 containing
individual targeting motifs, a combination of the N-terminal IC
motif and the C-terminal GpIIa motif had a negative effect, but
not the expected synergistic effect, on DC antigen presentation
to CD4 T cells. This is probably due to the utilization of
different adaptor proteins and endosome/lysosome-targeting
FIG. 4. A single dose of IC.BVP22 DNA vaccine primes T- and
B-lymphocyte responses. (A) F2-5-specific IFN-
 CD4 responses.
An asterisk denotes statistically significant differences between the
IC.BVP22 group mean and both the BVP22R and the VR-1055 vector
group means, whereas a dagger denotes a lack of a statistically signif-
icant difference between the BVP22R and the VR-1055 vector group
means. (B) F2-5-specific CD4 T-cell proliferation. The double dagger
denotes statistically significant differences between the IC.BVP22 vec-
tor group mean and both the BVP22R and the VR-1055 vector group
means, whereas a section sign denotes a lack of a statistically signifi-
cant difference between the BVP22R and the VR-1055 vector group
means. (C) IgG titers against the defined MSP1a B-cell epitope linked
to F2-5. A paragraph sign denotes statistically significant differences
between the IC.BVP22 vector group mean and both the BVP22R and
the VR-1055 vector group means, whereas double vertical lines denote
a lack of a statistically significant difference between the BVP22R and
the VR-1055 vector group means. All responses were measured 11
days following a single DNA vaccine immunization. The bars represent
group means, and the arrows point to the responses detected in calves
3937 and 3959.
308 MWANGI ET AL. CLIN. VACCINE IMMUNOL.
pathways by these two targeting motifs. Endosome/lysosome
targeting of MHC class II invariant-chain complexes is medi-
ated by a dileucine-based signal in the IC motif that binds to
the AP-2 complex, which is a component of the clathrin coats,
which are involved in vesicle formation and cargo sorting.
Apparently, AP-2 is associated only with the plasma mem-
brane, and thus, a significant pool of MHC class II molecules
traffic to the endosomal/lysosomal system by means of the cell
FIG. 5. IC.BVP22 DNA vaccine-primed immune responses are main-
tained and expanded following a single immunization. The kinetics of the
postimmunization responses were evaluated weekly; and the results from
day 95, representative of the response throughout the post-single-immu-
nization period, are shown. (A) F2-5-specific IFN-
 PBMC responses;
(B) F2-5-specific PBMC proliferation; (C) IgG titers against the defined
MSP1a B-cell epitope linked to F2-5. The bars represent group means,
and asterisks denote a statistically significant difference between the
IC.BVP22 vaccinees and calves identically vaccinated but vaccinated with
the control BVP22R. Arrows point to the responses of the IC.BVP22
vaccinee (calf 3937) that initially had the lowest responses 11 days postim-
munization and the responses of calf 3959.
FIG. 6. IC.BVP22 DNA vaccine-primed memory responses un-
dergo rapid recall. (A) F2-5-specific IFN-
 PBMC responses; (B) F2-
5-specific PBMC proliferation; (C) IgG responses against the MSP1a
B-cell epitope linked to F2-5. All responses were measured 96 h after
the calves were reexposed by inoculation of MSP1aBT on day 105. The
bars represent group means, and asterisks denote statistically signifi-
cant differences between the IC.BVP22 vaccinees and the calves inoc-
ulated with the control BVP22R construct. Arrows point to the re-
sponses of the IC.BVP22 vaccinee (calf 3937) that initially had the
lowest responses 11 days postimmunization.
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surface (21). In contrast, the lysosome-targeting motif from
LAMP-1 binds to AP-3, and the resultant complex is directly
transported from the trans-Golgi network to the endosome/
lysosome compartments (20). Consequently, a combination of
the two targeting motifs could have been antagonistic rather
than synergistic in directing the antigen targeting the endo-
some/lysosome compartments.
Immunization of calves at a DC-enriched intradermal site
with a single dose of the IC.BVP22 DNA vaccine targeting key
intercellular and intracellular events significantly enhanced the
priming and expansion of antigen-specific CD4 T-cell and
B-cell responses. This response to a single DNA immuniza-
tion suggests that the inclusion of the intercellular trafficking
BVP22 domain and the IC intracellular targeting motif signif-
icantly enhanced priming. This is consistent with our demon-
stration that IC.BVP22 significantly enhanced greater DC pre-
sentation of a CD4 T-cell epitope to cognate T cells than
BVP22 alone and BVP22.GpIIa in vitro. This is also consistent
with the previous demonstration that IC motif-directed endo-
some/lysosome targeting of an endogenously expressed antigen
enhances MHC class II presentation (30, 32). Whether this
enhanced priming of immune responses in IC.BVP22 vaccin-
ees is attributable to the BVP22-directed intercellular spread-
ing alone or the IC motif-dependent endosome/lysosome tar-
geting alone, the additive or synergistic effects of the two
signals cannot be determined by use of the present study de-
sign, in which only the optimal in vitro construct was tested in
vivo. Priming was detected in all the IC.BVP22 vaccinees, but
there was clear heterogeneity in the responses, with the same
individual (calf 3937) having the fewest IFN-
-secreting CD4
T cells; the lowest level of T-cell proliferation; and, along with
another cohort, the lowest antibody titer. This cannot be at-
tributed simply to the MHC haplotype, as a second vaccinee in
the IC.BVP22 group, calf 3959, shared identical haplotypes yet
had a higher-magnitude response (Table 1 and Fig. 4A to C).
This heterogeneity among outbred animals, even when they
share MHC haplotypes, is consistent with previous observa-
tions of marked variation in the responses of human vaccinees
expressing a relevant MHC allele capable of presenting a spe-
cific epitope (33). It is important to emphasize that the goal is
not to generate a uniform maximal response in all vaccinees,
which is an unlikely result, given the genetic heterogeneity of
outbred animals and humans, but to increase the percentage of
vaccinees that are primed with a single immunization. The
priming in all vaccinees following a single immunization with
IC.BVP22 fulfills this criterion.
An attractive feature of the original DNA vaccine concept
was that continued antigen expression would result in expan-
sion and maintenance of the immune response without the
need for an additional booster. The immune responses primed
by the single IC.BVP22 DNA vaccine immunization increased
and were maintained throughout the postpriming period. Im-
portantly, there was a significant expansion of immune re-
sponses in calf 3937, which initially had the lowest responses.
Vaccine-induced protection from infectious diseases relies on
the effective generation and preservation of specific immuno-
logical memory. Priming by the single IC.BVP22 DNA vaccine
immunization induced memory T- and B-cell responses that
underwent rapid recall in all the vaccinees, which demon-
strated that effective memory had been induced, regardless of
the heterogeneity in the magnitude of the initial responses.
These results demonstrate that DNA vaccines targeting key
intercellular and intracellular events significantly enhance
priming and expansion and support the feasibility of single-
dose DNA immunization in outbred populations.
Priming is the critical event that determines whether a spe-
cific immunological memory is established, and thus, an effi-
cacious vaccine must consistently prime significant immune
responses in the target vaccine population. Achieving this with
a single immunization is a critical need in terms of both human
and animal vaccine programs. In addition to the issue of de-
creased compliance associated with the need for repeated
boosters and the economic considerations of repeated vacci-
nation of livestock, the efficacy of mass vaccination campaigns
in response to disease outbreaks will be enhanced by an effi-
cacious single immunization. In the present study, we used a
first inoculation of DNA-encoded FLT3L and GM-CSF as
molecular adjuvants to create a DC-rich intradermal site, fol-
lowed 72 h later by the single immunization of the DNA vac-
cine. A clear next step is to coadminister the DNA-encoded
molecular adjuvants and the IC.BVP22 vaccine at the same
time, a strategy that should be effective, as DNA constructs
encoding BVP22 have been shown to enhance intercellular
trafficking and the uptake of linked antigen for greater than 6
days (23). The development of a single-dose DNA vaccine for
the codelivery of DC recruitment factors and immunogen
would represent a substantial step forward for the actual de-
ployment of DNA vaccines for use in outbred animals. Finally,
while the DNA vaccine vector modifications tested in the
present study are unique and clearly meet the priming criteria,
there are additional targeting modifications reported in the
literature that have been shown to be efficacious in murine
models (11, 16, 19). We support the testing of novel vectors in
outbred species, such as the calf model used in this study, to
identify those modifications that enhance the priming and ex-
pansion of immune responses in a genetically heterogeneous
vaccinee population. These studies are necessary to bridge the
gap between the mouse models of immunization and the need
for improved vaccines for animal and human populations.
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